There are still a couple dozen tickets left for one of the most interestingly-cast performances of H.G. Wells, Orson Welles and Howard Koch's "War of the Worlds." On Saturday, Jan. 17,  generations of Star Trek actors will take on the world's most famous radio show.

The cast — directed by Jim Fall — features: René Auberjonois (“Star Trek: Deep Space Nine”), Michael Dorn (“Star Trek: TNG”), Dean Haglund (“The X-Files”), Walter Koenig ("Star Trek"), Linda Park ("Star Trek: Enterprise"), Jason Ritter (“The Event”), Tim Russ (“Star Trek: Voyager”), Armin Shimerman (“Star Trek: Deep Space Nine”) and Wil Wheaton, playing... Orson Welles.

The performance is a fundraiser for Sci-Fest LA, the new annual science fiction play festival, so tickets aren't cheap — but they're scarce, and this looks like a memorable night.

KPCC and "Off-Ramp" celebrated the 75th anniversary of the broadcast last year by distributing the original 1938 performance, and a new documentary, internationally... introduced by George Takei, another original Trek actor you might have heard of.

War of the Worlds: Sat., Jan. 17,  8 PM; The Acme Theatre, 135 North La Brea Ave. LA CA 90036

This content is from Southern California Public Radio. View the original story at SCPR.org.

A little girl licking a spoon after stirring the cake mixture in 1935. ; Credit: Fox Photos/Getty Images

“How in the world am I going to come up with something to make dinner tonight?”

If you’ve found yourself asking this question repeatedly during the pandemic, you’re not alone. Grocery shopping complicated by COVID-19 and shortages of certain staples has meant that many who might not usually consider themselves home chefs have had no choice but to throw an apron on and do some culinary experimentation with whatever they already have in their kitchen and pantry. 

Last month on AirTalk, we tackled this issue by calling up pro chef Noelle Carter and food writer Russ Parson, both of whom are former members of the L.A. Times’ Food team, to answer your questions about how to cook with what you already have, recycle  certain foods, and even make staples that you might not be able to find in abundance right now. If you tuned in last time, you learned how to make your own pasta, how to regrow vegetables like green onions and romaine lettuce, and even what you can use as a substitute for all-purpose flour if you can’t find any at the store.

Today on AirTalk, we’re bringing Noelle and Russ back to help you out in the kitchen! If you’ve got questions about things like making or substituting ingredients, or need some ideas for what to make out of random ingredients in your fridge, join our live conversation by calling 866-893-5722.

Guests:

Noelle Carter, chef, food writer and culinary consultant for Noelle Carter Food, a website sharing recipes, cooking techniques and helpful kitchen tips for the home cook; she is the former director of the Los Angeles Times Test Kitchen; she tweets @noellecarter

Russ Parsons, former food editor and columnist for The Los Angeles Times for more than 20 years; he is the author of two cookbooks: “How To Pick A Peach” and “How To Read A French Fry”; he tweets @Russ_Parsons1

This content is from Southern California Public Radio. View the original story at SCPR.org.

Texas Gov. Greg Abbott signed an executive order banning all elective medical procedures, including abortions, during the coronavirus outbreak. The ban extends to medication abortions.; Credit: Eric Gay/AP

Governors across the country are banning elective surgery as a means of halting the spread of the coronavirus. But in a handful of states that ban is being extended to include a ban on all abortions.

So far the courts have intervened to keep most clinics open. The outlier is Texas, where the U.S. Court of Appeals for the Fifth Circuit this week upheld the governor's abortion ban.

Four years ago, Texas was also the focus of a fierce legal fight that ultimately led to a U.S. Supreme Court ruling in which the justices struck down a Texas law purportedly aimed at protecting women's health. The court ruled the law was medically unnecessary and unconstitutional.

Now Texas is once again the epicenter of the legal fight around abortion. In other states--Ohio, Iowa, Alabama, and Oklahoma--the courts so far have sided with abortion providers and their patients.

Not so in Texas where Gov. Greg Abbott signed an executive order barring all "non-essential" medical procedures in the state, including abortion. The executive order was temporarily blocked in the district court, but the Fifth Circuit subsequently upheld the governor's order by a 2-to-1 vote, declaring that "all public constitutional rights may be reasonably restricted to combat a public health emergency."

"No more elective medical procedures can be done in the state because of the potential of needing both people ... beds and supplies, and obviously doctors and nurses," said Texas Attorney General Ken Paxton in an interview with NPR.

'Exploiting This Crisis'

Nancy Northrup, CEO of the Center for Reproductive Rights, sees things very differently. "It is very clear that anti-abortion rights politicians are shamelessly exploiting this crisis to achieve what has been their longstanding ideological goal to ban abortion in the U.S.," she said.

Paxton denies that, saying Texas "is not targeting any particular group."
The state's the "only goal is to protect people from dying," he said.

Yet the American Medical Association just last week filed a brief in this case in support of abortion providers, as did 18 states, led by New York, which is the state that has been the hardest hit by the coronavirus.

They maintain that banning abortion is far more dangerous,because it will force women to travel long distances to get one. A study from the Guttmacher Institute found that people seeking abortions during the COVID-19 outbreak would have to travel up to 20 times farther than normal if states successfully ban abortion care during the pandemic. The AMA also notes that pregnant women do not stop needing medical care if they don't get an abortion.

Northrup, of the Center for Reproductive Rights, sees this as more evidence that the ban is a calculated move by the state: what "puts the lie to this is the fact that they're trying to ban medication, abortion as well; that's the use of pills for abortion.

"Those do not need to take place in a clinic and they can be done, taken effectively by tele-medicine. So it shows that the real goal here, tragically, is shutting down one's right to make the decision to end the pregnancy, not a legitimate public health response."

'I Was Desperate'

Affidavits filed in the Texas case tell of harrowing experiences already happening as the result of the Texas ban. One declaration was filed by a 24-year-old college student. The week she lost her part-time job as a waitress, she found out she was pregnant. She and her partner agreed they wanted to terminate the pregnancy, and on March 20 she went to a clinic in Forth Worth alone; because of social distancing rules, her partner was not allowed to go with her.

Since she was 10 weeks pregnant, still in her first trimester, she was eligible for a medication abortion. Under state law, she had to wait 24 hours before getting the pills at the clinic, but the night before her scheduled appointment, the clinic called to cancel because of Abbott's executive order.

He partner was with her and we "cried together," she wrote in her declaration. "I couldn't risk the possibility that I would run out of time to have an abortion while the outbreak continued," and it "seemed to be getting more and more difficult to travel."

She made many calls to clinics in New Mexico and Oklahoma. The quickest option was Denver--a 12-hour drive, 780-mile drive from where she lives. Her partner was still working, so her best friend agreed to go with her. They packed sanitizing supplies and food in the car for the long drive and arrived at the Denver Clinic on March 26, where she noticed other cars with Texas plates in the parking lot, according to the affidavit.

At the clinic, she was examined, given a sonogram again, and because Colorado does not have a 24-hour waiting requirement, she was given her first abortion pill without delay and told she should try to get home within 30 hours to take the second pill.

She and her friend then turned around to go home. They were terrified she would have the abortion in the car, and tried to drive through without taking breaks. But after six hours, when it turned dark they were so exhausted they had to stop at a motel to catch some sleep. The woman finally got home and took the second pill just within the 30-hour window.

She said that despite the ordeal she was grateful she had the money, the car, the friend, and the supportive partner with a job, to make the abortion possible. Others will not be so lucky, she wrote. But "I was desperate and desperate people take desperate steps to protect themselves."

A 'Narrative' Of Choice

Paxton, the Texas attorney general, does not seem moved by the time limitations that pregnancy imposes, or the hardships of traveling out of state to get an abortion. He told NPR "the narrative has always been 'It's a choice' ... that's the whole narrative. I'm a little surprised by the question, given that's always been the thing."

On Thursday abortion providers and their patients returned to the district court in Texas instead of appealing directly to the U.S. Supreme Court to overturn the Fifth Circuit's ruling from earlier this week. The district court judge, who originally blocked the governor's ban, instead narrowed the governor's order so that medical abortions--with pills--would be exempt from the ban, as well as abortions for women who are up against the state-imposed deadline. Abortions in Texas are banned after 22 weeks.

In the end, though, this case may well be headed to the U.S. Supreme Court. And because of the addition of two Trump appointees since 2016--the composition of the court is a lot more hostile to abortion rights.

This content is from Southern California Public Radio. View the original story at SCPR.org.

The L.A. Philharmonic will be the new operator of the John Anson Ford Theatre, the smaller outdoor venue near  the 101 Freeway across from the Hollywood Bowl, under a plan approved by the Los Angeles County Board of Supervisors.  

L.A.  funding sustains the Ford, and the county recently spent $80 million renovating the 1,200  seat amphitheater.  But attendance has been lackluster — and Supervisor Sheila Kuehl hopes the L.A. Philharmonic can change that. 

“The Ford will be able to take advantage of the natural synergies in marketing, capacity-building and program resources that simply haven’t been available to the Ford as an independent institution," she  said.

The move by the L.A. County  blindsided many local artists.  They say the Ford is an important incubator for diverse talent.  They also worry ticket prices will increase.  Prompted by their criticism, the Supervisors will require the Phil to meet with artists and annually review the diversity of the Ford’s shows with county officials.

This content is from Southern California Public Radio. View the original story at SCPR.org.

; Credit: Illustration: Dan Carino

Read the full article at LAist

Coronavirus deaths in the U.K. have passed those in Italy. Workers in the intensive care unit at the Royal Papworth Hospital in Cambridge are shown gearing up to care for COVID-19 patients.; Credit: Neil Hall/AP

Over 32,000 people have died from the new coronavirus in the United Kingdom, according to the Office for National Statistics, marking the first time in the pandemic that it has led Europe in the number of deaths.

The country has surpassed Italy in COVID-19 deaths. The U.S. still leads the world in the highest number of coronavirus deaths; over 70,270 had died from the disease as of Tuesday.

The number of total deaths recorded in the U.K. is "higher than we would wish, I think is all I can say," Angela McLean, chief scientific adviser of Ministry of Defence said during the country's press briefing Tuesday.

McLean also emphasized that deaths in U.K. care homes have been steadily rising and said the trend was something the country "need[s] to get to grips with."

"I don't think we'll get a real verdict on how well countries have done until the pandemic is over," British Foreign Secretary Dominic Raab said Tuesday. "And particularly until we have comprehensive international data on all causes of mortality."

Since different countries collect and report coronavirus data using different methods, the comparisons between regions are not perfect. As more time passes and more tests are conducted and more data comes in, coronavirus death rates will become more precise.

The peak in deaths comes as other European countries, including Italy and Spain, are easing shelter-in-place restrictions, while U.K. Prime Minister Boris Johnson is expected to modify Britain's orders in the next week.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Remdesivir, an experimental antiviral drug made by Gilead Sciences, has been authorized by the Food and Drug Administration for emergency use in treating severely ill COVID-19 patients.; Credit: Ulrich Perry/POOL/AFP via Getty Images

Now that the Food and Drug Administration has authorized remdesivir for emergency use in seriously ill COVID-19 patients, the experimental drug is another step closer to full approval. That's when most drugs get price tags.

Gilead Sciences, which makes remdesivir, is donating its initial supply of 1.5 million doses, but the company has signaled it will need to start charging for the drug to make production sustainable. It's unclear when that decision might be made.

"Going forward, we will develop an approach that is guided by the principles of affordability and access," Gilead CEO Daniel O'Day told shareholders during the company's annual meeting Wednesday.

In a quarterly financial filing made the same day, Gilead said its investment in remdesivir this year "could be up to $1 billion or more," much of it for scaling up manufacturing capacity.

The company also acknowledged that it's in the spotlight. "[G]iven that COVID-19 has been designated as a pandemic and represents an urgent public health crisis, we are likely to face significant public attention and scrutiny about any future business models and pricing decisions with respect to remdesivir," Gilead said in the quarterly filing.

How will the company balance its business calculations with the drug's potential value to society?

"Gilead has not yet set a price for remdesivir," company spokeswoman Sonia Choi wrote in an email to NPR. "At this time, we are focused on ensuring access to remdesivir through our donation. Post-donation, we are committed to making remdesivir both accessible and affordable to governments and patients around the world."

Among potential treatments for COVID-19, remdesivir, an intravenous drug that was once studied for Ebola, is one of the furthest along.

"It's hard to imagine a situation in which there will be more public scrutiny," said Michael Carrier, a professor at Rutgers School of Law who specializes in antitrust and pharmaceuticals. "On the one hand, Gilead will try to recover its R&D in an atmosphere in which it is able to potentially make a lot of money. On the other hand, the pressure will be intense not to charge what's viewed as too high a price."

Breaking with its usual practices, the Institute for Clinical and Economic Review, or ICER, an influential nonprofit that analyzes drug pricing, issued an expedited report on remdesivir.

"Under normal circumstances, we would be unlikely to do a report when the evidence is this raw and immature," ICER President Steven Pearson said in an interview with NPR. "But it was quite clear that the world is moving at a much quicker pace."

If the price is based just on the cost of making the drug, then a 10-day course of remdesivir should cost about $10, according to the ICER report. (Gilead said results of a recently completed study suggest a five-day course of treatment may be just as effective.)

But if the drug is priced based on the drug's effectiveness, ICER estimates it should cost around $4,500 — assuming the drug is proven to have some benefit on mortality. If it doesn't and the drug only shortens hospital stays, that value-based price goes down to $390.

Results from a federally funded study described by Anthony Fauci, director of the National Institute for Allergy and Infectious Diseases, suggested that remdesvir could reduce recovery time by a median of four days — 11 days to recovery for patients treated with remdesivir compared with 15 days for those who got a placebo. A potential survival benefit is less clear.

Rutgers's Carrier said he expects Gilead to set the remdesivir price somewhere between the $10 and $4,500 that ICER estimated. The company has already shown that it can respond to public pressure when it asked the FDA to rescind the orphan drug status it won for remdesivir, he pointed out.

"When you see that $10 figure, that sets a benchmark for a figure that is eminently affordable," Carrier said. Ultimately, he said a price more than $1,000 per treatment course would be unpopular.

Gilead "will be watched very carefully," he said, because of its prior history of pricing. He referred to two other Gilead drugs that drew scrutiny over high price tags. The company charged $1,000 per pill for Sovaldi, a cure for hepatitis C. And its HIV drug Truvada can cost $22,000 per year.

But there is such a thing as pricing remdesivir too low, said Craig Garthwaite, who directs the health care program at Northwestern University's Kellogg School of Management.

"We don't think this is the only drug we need," he said, adding that remdesivir doesn't appear to be a "home run" against the coronavirus, based on existing data. "The thing that would worry me the most is that we're somehow telling people that if you take the risky bet to try, and you'll go after a coronavirus cure and you do it, you're not going to get paid."

Instead, he said he would like to see acceptance of a generous price for remdesivir to send the message to drug companies that the best thing they can do is "dedicate every waking moment to trying to develop that cure, and that if they do that, we will pay them the value they create," he said.

During a Gilead earnings call on April 30, analysts asked executives whether they could expect similar financial returns on remdesivir as they've seen with Gilead's other drugs.

"There is no rulebook out there, other than that we need to be very thoughtful about how we can make sure we provide access of our medicines to patients around the globe," Gilead CEO O'Day said. "And do that in a sustainable way for the company, for ... shareholders, and we acknowledge that."

On May 1, the FDA authorized remdesivir for emergency use, meaning it will be easier to administer to hospitalized patients with severe disease during the pandemic, but the drug is not yet officially approved. The federal government is coordinating distribution of the treatment.

Day acknowledged on the recent earnings call that the company "could" charge for remdesivir under an emergency use authorization, but he stressed that Gilead is donating its current supply, which should last through "early summer."

To date, the National Institutes of Health said it has obligated $23 million toward its COVID-19 remdesivir trial. And the U.S. Army Medical Research Institute of Infectious Diseases did some of the early in vitro and animal studies with the medicine prior to the pandemic.

"Taxpayers are often the angel investors in pharmaceutical research and development, yet this is not reflected in the prices they pay," Reps. Lloyd Doggett, D-Texas, and Rosa DeLauro, D-Conn., wrote in a April 30 letter to Health and Human Services Secretary Alex Azar.

Concerned about remdesivir's price, they asked for a full breakdown of taxpayer funds that have gone toward the development of the medicine. "An unaffordable drug is completely ineffective," they wrote in the letter. "The substantial taxpayer investments in COVID-19 pharmaceutical research must be recognized."

This content is from Southern California Public Radio. View the original story at SCPR.org.

LOS ANGELES, CA - SEPTEMBER 29: Yasiel Puig #66 of the Los Angeles Dodgers walks onto the field to start the game against the Colorado Rockies at Dodger Stadium on September 29, 2013 in Los Angeles, California. (Photo by Lisa Blumenfeld/Getty Images); Credit: Lisa Blumenfeld/Getty Images

There are 162 games in the regular season of a major league baseball team, and I have watched exactly … hm … none. Spring, summer, autumn, as the Dodgers died and rose from the dead, I wasn’t looking.

But now, like almost everyone else in L.A., I will be cheering them in the playoffs, cheering them to their first World Series game since Michael Dukakis ran for president.

I am that deplorable creature: The fair-weather fan.

I like sports just fine, but my sport is football.

They say baseball is a relaxing game. Boy, is it!  You can eat, doze, eat again, and it’s still the fourth inning. I’ve tried to love baseball, I really have. But the diamond can’t beat the gridiron when it comes to football’s built-in thrill advantage: At any possible second, the football can change hands, the defense becomes the offense … and score!

Just about the best time I ever had at Dodger Stadium was watching the pope round the bases in his Popemobile, when he visited L.A. That was the year before the Dodgers won the World Series for the last time. I hear baseball players are superstitious; maybe it’s time to invite the new pope for a return engagement.

Kitty Felde – now there’s a fan. She’s even written plays about baseball! But she’s way back in the nation’s capital, stuck with the Washington Nationals to root for.

A paradox

It’s a paradox, really. I’ve interviewed the former Dodgers owner, Peter O’Malley, who is a truly wonderful man. I’ve interviewed Carl Erskine, the Dodgers pitcher who goes back to the Brooklyn days, and a sweeter guy you could never meet. I know Roz Wyman, the First Fan, the city councilwoman who worked the magic to bring the Dodgers here from Brooklyn.  I interviewed the McCourts, back when they were still a plural. The L.A. Times once sent me to write about Fernando Valenzuela’s hometown in Mexico, back when El Zurdo started burning up the mound at Chavez Ravine. And I sat with that gift of a man, Vin Scully, at Dodger Stadium, as the team warmed up on the jewel-box beautiful field.

None of that made a true baseball believer of me. Instead, I pine like Juliet for a pro football team. O Dodgers, Dodgers, wherefore art thou the Dodgers, and not the Green Bay Packers?

But I would be thrilled if the Dodgers took the whole baseball enchilada – thrilled, because I am an Angeleno, and the Dodgers are that rare civic institution that ties us all together, even if you don’t know a base hit from base ten.

And that makes me as entitled as the next local to put on my Dodger Blue and holler my heart out, and cheer them all the way to the World Series.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Pedestrians walk by the Castro Theatre that has a marquee announcing that they are closed due to a statewide ordinance banning gatherings of more than 250 people in San Francisco, California. ; Credit: Justin Sullivan/Getty Images

Hollywood has come to a stand still. The film and entertainment industry has been hit hard by the coronavirus outbreak as theaters close, film releases and events are being postponed, and studios are putting a pause on film production.

The gravity of the coronavirus is being felt all throughout the country and Hollywood is not coming out of the outbreak unscathed. Social distancing measures being enforced to help control the outbreak has studios and theatres taking a huge hit. It’s predicted that about 170,000 people in the film industry will lose their jobs. Many of the lowest-paid positions and freelance jobs have been the first to go. From events to films, the industry is trying to strategize around the outbreak with no clear picture on how long these conditions could last. Hollywood unions, activist groups and nonprofits are coming together to help provide some kind of emergency relief for workers who are getting hit the hardest. It’s been a period of economic shock for the entertainment industry and it’s still too early to see what Hollywood could look like after the outbreak is over.

Today on AirTalk, we check-in with people in the entertainment industry who have been impacted by the outbreak and where might Hollywood go from here. If you work in entertainment, we'd like to hear from you! How are you coping as most productions are shut down? Join the live conversation by calling 866-893-5722.

Guest:

Andrew Wallenstein, co-editor-in-chief at Variety; he tweets @awallenstein

This content is from Southern California Public Radio. View the original story at SCPR.org.

Kunjue Li (L) and Hing Chi-Lee (R) in Tigertail.; Credit: Netflix/Tigertail (2020)

Larry Mantle and KPCC film critics Claudia Puig, Tim Cogshell and Charles Solomon review this weekend’s new movie releases and share their recommendations for what to binge-watch while you’re stuck at home during COVID-19.

• "Tigertail" on Netflix

• "School Life" on Netflix

• "Love. Wedding. Repeat." on Netflix

• 'Stray Dolls" on VOD (AppleTV, Google Play Redbox * FandangoNOW

• "Sea Fever" on VOD (Spectrum On Demand, AppleTV, Google Play, Vudu, Redbox & FandangoNOW)

• "Strike" on VOD (Redbox, FandangoNOW & Vudu)

• "The Main Event" on Netflix

Guests:

Claudia Puig, film critic for KPCC and president of the Los Angeles Film Critics Association (LAFCA); she tweets @ClaudiaPuig

Tim Cogshell, film critic for KPCC, Alt-Film Guide and CineGods.com; he tweets @CinemaInMind

Charles Solomon, film critic for KPCC, Animation Scoop and Animation Magazine

This content is from Southern California Public Radio. View the original story at SCPR.org.

The National Science Foundation: Creating knowledge to transform our future

A job seeker fills out an application during a career fair at the Southeast Community Facility Commission on May 21, 2014 in San Francisco; Credit: Justin Sullivan/Getty Images

California employers added 44,200 jobs in August, the largest gain of any state in the country. The state's unemployment rate stood still at 7.4 percent, compared to 6.1 percent nationwide.

"When the national numbers came out for August, and we saw a significant slowdown in job creation, we were a little bit concerned that we'd see the same thing happening here," said economist Kimberly Ritter-Martinez of the Los Angeles County Economic Development Corporation. "But in California, we stayed pretty much on track, outpacing the nation in terms of job creation." 

The construction sector was a huge contributor to California's job growth in August, with a gain of 13,600 jobs.  The other sectors with large gains were Education/Health Services (+12,200), and Professional/Business Services (+10,600). 

"We've been seeing steady increases in construction employment for some time, but it has been a slow steady increase," said Tom Holsman, CEO of the Associated General Contractors of California.

"Recent increases are attributable to many projects that have been in the early stages of startup gaining momentum," Holsman added, citing LA County Metro transit projects and the new Wilshire Grand Hotel construction project as local examples.

In Los Angeles County, the unemployment rate also stayed flat at 8.1 percent, but it remains far lower than the 9.9 percent of August of 2013. In the last twelve months, the L.A. County Metro area has gained 6,600 construction jobs, a rate of 5.6 percent.

Ritter-Martinez, of the LAEDC says other economic indicators support a boost in construction jobs at the Los Angeles and statewide levels: permits for new housing construction, remodeling, and non-residential construction are all on the rise. 

"Builders and developers are reporting that they're having trouble finding some skilled labor for construction," Ritter-Martinez said. "It's taken so long for that sector to come back, a lot of construction people have gone off and found other kinds of jobs or moved out of the region." 

In Orange County, the unemployment rate was 5.4 percent, down from 5.7 percent in July. The unemployment rate in the Riverside-San Bernardino-Ontario area was 8.7 percent in 
August 2014, down from a revised 9.3 percent in July 2014.

Remdesivir, an experimental antiviral drug made by Gilead Sciences, has been authorized by the Food and Drug Administration for emergency use in treating severely ill COVID-19 patients.; Credit: Ulrich Perry/POOL/AFP via Getty Images

Now that the Food and Drug Administration has authorized remdesivir for emergency use in seriously ill COVID-19 patients, the experimental drug is another step closer to full approval. That's when most drugs get price tags.

Gilead Sciences, which makes remdesivir, is donating its initial supply of 1.5 million doses, but the company has signaled it will need to start charging for the drug to make production sustainable. It's unclear when that decision might be made.

"Going forward, we will develop an approach that is guided by the principles of affordability and access," Gilead CEO Daniel O'Day told shareholders during the company's annual meeting Wednesday.

In a quarterly financial filing made the same day, Gilead said its investment in remdesivir this year "could be up to $1 billion or more," much of it for scaling up manufacturing capacity.

The company also acknowledged that it's in the spotlight. "[G]iven that COVID-19 has been designated as a pandemic and represents an urgent public health crisis, we are likely to face significant public attention and scrutiny about any future business models and pricing decisions with respect to remdesivir," Gilead said in the quarterly filing.

How will the company balance its business calculations with the drug's potential value to society?

"Gilead has not yet set a price for remdesivir," company spokeswoman Sonia Choi wrote in an email to NPR. "At this time, we are focused on ensuring access to remdesivir through our donation. Post-donation, we are committed to making remdesivir both accessible and affordable to governments and patients around the world."

Among potential treatments for COVID-19, remdesivir, an intravenous drug that was once studied for Ebola, is one of the furthest along.

"It's hard to imagine a situation in which there will be more public scrutiny," said Michael Carrier, a professor at Rutgers School of Law who specializes in antitrust and pharmaceuticals. "On the one hand, Gilead will try to recover its R&D in an atmosphere in which it is able to potentially make a lot of money. On the other hand, the pressure will be intense not to charge what's viewed as too high a price."

Breaking with its usual practices, the Institute for Clinical and Economic Review, or ICER, an influential nonprofit that analyzes drug pricing, issued an expedited report on remdesivir.

"Under normal circumstances, we would be unlikely to do a report when the evidence is this raw and immature," ICER President Steven Pearson said in an interview with NPR. "But it was quite clear that the world is moving at a much quicker pace."

If the price is based just on the cost of making the drug, then a 10-day course of remdesivir should cost about $10, according to the ICER report. (Gilead said results of a recently completed study suggest a five-day course of treatment may be just as effective.)

But if the drug is priced based on the drug's effectiveness, ICER estimates it should cost around $4,500 — assuming the drug is proven to have some benefit on mortality. If it doesn't and the drug only shortens hospital stays, that value-based price goes down to $390.

Results from a federally funded study described by Anthony Fauci, director of the National Institute for Allergy and Infectious Diseases, suggested that remdesvir could reduce recovery time by a median of four days — 11 days to recovery for patients treated with remdesivir compared with 15 days for those who got a placebo. A potential survival benefit is less clear.

Rutgers's Carrier said he expects Gilead to set the remdesivir price somewhere between the $10 and $4,500 that ICER estimated. The company has already shown that it can respond to public pressure when it asked the FDA to rescind the orphan drug status it won for remdesivir, he pointed out.

"When you see that $10 figure, that sets a benchmark for a figure that is eminently affordable," Carrier said. Ultimately, he said a price more than $1,000 per treatment course would be unpopular.

Gilead "will be watched very carefully," he said, because of its prior history of pricing. He referred to two other Gilead drugs that drew scrutiny over high price tags. The company charged $1,000 per pill for Sovaldi, a cure for hepatitis C. And its HIV drug Truvada can cost $22,000 per year.

But there is such a thing as pricing remdesivir too low, said Craig Garthwaite, who directs the health care program at Northwestern University's Kellogg School of Management.

"We don't think this is the only drug we need," he said, adding that remdesivir doesn't appear to be a "home run" against the coronavirus, based on existing data. "The thing that would worry me the most is that we're somehow telling people that if you take the risky bet to try, and you'll go after a coronavirus cure and you do it, you're not going to get paid."

Instead, he said he would like to see acceptance of a generous price for remdesivir to send the message to drug companies that the best thing they can do is "dedicate every waking moment to trying to develop that cure, and that if they do that, we will pay them the value they create," he said.

During a Gilead earnings call on April 30, analysts asked executives whether they could expect similar financial returns on remdesivir as they've seen with Gilead's other drugs.

"There is no rulebook out there, other than that we need to be very thoughtful about how we can make sure we provide access of our medicines to patients around the globe," Gilead CEO O'Day said. "And do that in a sustainable way for the company, for ... shareholders, and we acknowledge that."

On May 1, the FDA authorized remdesivir for emergency use, meaning it will be easier to administer to hospitalized patients with severe disease during the pandemic, but the drug is not yet officially approved. The federal government is coordinating distribution of the treatment.

Day acknowledged on the recent earnings call that the company "could" charge for remdesivir under an emergency use authorization, but he stressed that Gilead is donating its current supply, which should last through "early summer."

To date, the National Institutes of Health said it has obligated $23 million toward its COVID-19 remdesivir trial. And the U.S. Army Medical Research Institute of Infectious Diseases did some of the early in vitro and animal studies with the medicine prior to the pandemic.

"Taxpayers are often the angel investors in pharmaceutical research and development, yet this is not reflected in the prices they pay," Reps. Lloyd Doggett, D-Texas, and Rosa DeLauro, D-Conn., wrote in a April 30 letter to Health and Human Services Secretary Alex Azar.

Concerned about remdesivir's price, they asked for a full breakdown of taxpayer funds that have gone toward the development of the medicine. "An unaffordable drug is completely ineffective," they wrote in the letter. "The substantial taxpayer investments in COVID-19 pharmaceutical research must be recognized."

This content is from Southern California Public Radio. View the original story at SCPR.org.

Full Text:

What an animal eats is a fundamental aspect of its biology, but surprisingly, the evolution of diet had not been studied across the animal kingdom until now. Scientists at the University of Arizona report several unexpected findings from taking a deep dive into the evolutionary history of more than one million animal species and going back 800 million years, when the first animals appeared on our planet. The study revealed several surprising key insights: Many species living today that are carnivorous, meaning they eat other animals, can trace this diet back to a common ancestor more than 800 million years ago; A plant-based, or herbivorous, diet is not the evolutionary driver for new species that it was believed to be; Closely related animals tend to share the same dietary category -- plant-eating, meat-eating, or both. This finding implies that switching between dietary lifestyles is not something that happens easily and often over the course of evolution.

Image credit: Daniel Stolte/UANews

The National Science Foundation: Creating knowledge to transform our future

A view of the Q1 2020 threat landscape as seen by ESET telemetry and from the perspective of ESET threat detection and research experts

The post ESET Threat Report appeared first on WeLiveSecurity

Scammers rehash old campaigns, create credit card-stealing websites and repurpose information channels to milk the COVID-19 crisis for all it's worth

The post It’s no time to let your guard down as coronavirus fraud remains a threat appeared first on WeLiveSecurity

Source: Streetwise Reports   05/01/2020

Seattle Genetics Inc. (SGEN:NASDAQ) yesterday announced financial results for the first quarter ended March 31, 2020.

The company also provided an update on commercial results achieved in the quarter for its lead medicines including ADCETRIS® (brentuximab vedotin) and PADCEV^™ (enfortumab vedotin-ejfv) and the U.S. Food and Drug Administration's (FDA) approval and launch of TUKYSA^™ (tucatinib).

The company's President and CEO Clay Siegall, Ph.D., commented, "We have had a remarkable start to 2020, delivering record product sales in the first quarter that are now coming from both ADCETRIS and PADCEV. Notably, strong PADCEV sales in the first full quarter of launch reflect the unmet need among patients with metastatic bladder cancer...With the recent approval of TUKYSA for patients with metastatic HER2-positive breast cancer, we have now launched our third product just four months after our second...We are also preparing for European commercial operations and have hired general managers in major European markets ahead of potential ex-U.S. approvals of TUKYSA. With two new products, growing revenues, and an advancing pipeline of novel cancer programs, we have exciting prospects for future growth."

The company highlighted that ADCETRIS net sales in the U.S. and Canada increased by 22% to $164.1 million in Q1/20, compared to $135 million in Q1/19. The firm indicated that PADCEV net sales in the U.S. reached $34.5 million in Q1/20, which was its first full quarter of commercialization. The company added that royalty revenues in Q1/20 were $20.4 million and collaboration and license agreement revenues in Q1/20 totaled $15.6 million.

The firm reported a net loss for Q1/20 of $168.4 million, or $0.98 per diluted share, compared to net loss of $13.3 million, or $0.08 per diluted share for Q1/19. The company explained that "the net loss in Q1/20 included a net investment loss of $59.1 million primarily associated with its common stock holdings in Immunomedics, which are marked-to-market, compared to a net investment gain of $38.1 million in Q1/19."

The company advised that its TUKYSA was approved by the FDA for patients with HER2-positive metastatic breast cancer who have received one or more prior anti-HER2 regimens in the metastatic setting. The firm mentioned that it also expects to be able to report topline data in late Q2/20 or Q3/20 for the innovaTV 204 pivotal trial of tisotumab vedotin in patients with recurrent and/or metastatic cervical cancer who have relapsed or progressed after standard of care treatment.

The company noted that it is regularly monitoring the effects of the COVID-19 situation and is maintaining its business outlook estimates for FY/20 that it provided previously on February 6, 2020. For FY/20 it expects ADCETRIS net product sales of $675–700 million, royalty revenues of $105–115 million and collaboration and license agreement revenues of $30–50 million. The firm advised that for FY/20 it expects that R&D expenses will range from $860–950 million with SG&A expenses of $475–525 million.

Seattle Genetics is headquartered in Bothell, Wash., and is a global biotechnology company focused on discovering and commercializing cancer medicines.

Seattle Genetics has a market capitalization of around $23.7 billion with approximately 172.5 million shares outstanding. SGEN shares opened 2.75% higher today at $141.00 (+$3.77, +2.75%) over yesterday's $137.23 closing price and reached a new 52-week high price this morning of $157.00. The stock has traded today between $140.05 and $157.00 per share and is currently trading at $148.51 (+$11.28, +8.22%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

( Companies Mentioned: SGEN:NASDAQ, )

A recap of Parsley Energy's Q1/20 performance and projections for this year and next are given in a Raymond James report.

A new study indicates that water management in the Netherlands uses a reliable warning system for extreme weather, which can incorporate wind and coastal surge level forecasts, as well as precipitation forecasts.

A new German study suggests that residents??? level of satisfaction with their urban neighbourhood can be predicted from their perceptions of multiple and co-occurring burdens, such as poor air quality, lack of green space, noise and low cleanliness.

Heat waves are predicted to become more frequent under climate change, and are likely to be particularly severe in cities and towns due to the Urban Heat Island effect (UHI). A recent UK study of UHI mitigation strategies has demonstrated that even a small urban river can result in a cooling effect of 1??C during temperatures higher than 20??C, and that these cooling effects can be improved by careful urban design of the surrounding areas.

A recent study compared the decentralised treatment of pharmaceutical contaminants in wastewater at hospitals with centralised treatment at conventional and upgraded wastewater plants. The results suggest that additional (post) treatments may not always provide significant benefits.

Groundwater is the earth’s largest freshwater resource and is vital for irrigation and global food production. In dry periods farmers pump groundwater to water crops, this is already happening at an unsustainable level in many places — exceeding the rate at which rain and rivers can refill the groundwater stores. This study seeks to identify where groundwater pumping is affecting stream flows and estimates where and when environmentally critical stream flows — required to maintain healthy ecosystems — can no longer be sustained.

In Sweden, 63% of areas designated as Special Protection Areas (SPAs) for endangered birds are impacted by major roads or train lines, according to a new study. The research showed that 126 000 hectares (ha), or 4.2% of the SPAs, fall within 1 km of a road or train line, leading to a predicted 1% loss in bird abundance. The problem is greater in the south of the country, where 25.8% of land designated as SPA falls within 1 km of a road or rail line, representing an estimated 4 to 7% reduction in birds’ abundance within SPAs.

An early-warning system developed by researchers could help forest managers in Europe predict which trees are at greatest risk of bark- beetle infestation. The study looked at the probability of bark-beetle outbreaks on two important conifer-tree species in Slovenia: the Norway spruce (Picea abies) and silver fir (Abies alba). It found that high temperatures, and extreme weather linked to climate change — including droughts and ice storms — weakened trees, making them more vulnerable to attack by bark beetles.

Microsoft Edge is now giving users the ability to hide those pesky browser notification dialog boxes that are commonly used by web sites to push their content, or even spam, on visitors. [...]

A new framework to help decide whether to translocate species that are threatened by climate change has been developed. The framework provides a simple method of assessing different strategies and ensuring that limited budgets are used effectively.

A map of science could assist research planning strategies by helping to identify emerging topics. The map — which is based on links to almost 20 million scientific articles that have been published over the past 16 years — clusters and links scientific disciplines by citation-based relationships and serves as a highly detailed and scalable infographic. The authors hope it will be used by research planners to help distinguish — and potentially forecast — the research areas in science which have longevity, and also those which are innovative.

As the media environment changes, the way scientists communicate their work must also evolve. This study explored the effect of public communication on the scientific ‘impact’ of America’s most highly cited nanotechnology researchers. It provides the first evidence that outreach activities, such as speaking to journalists and being mentioned on Twitter, can increase a scientist’s impact.

A recent study has revealed that grassland plots planted with a mixture of several agricultural plant species produced a greater yield than plots planted with a single species. The findings provide valuable evidence for scientists, farmers and policymakers who strive to increase the productivity of grassland, while reducing input of nitrogen fertilisers.

The reduction in summer storms in the western Mediterranean could be partly caused by land use change on coasts and mountain slopes, a new study reports. This lack of storms causes water vapour to build up above the region and may lead to heavy rainfall and flooding in central Europe.

A new study suggests gaps exist in the treatment of depression with many individuals who screen positive for the mental health disorder not receiving treatment, according to an article published online by JAMA Internal Medicine.

read more

28 Aug 2016: The Mediterranean diet is associated with a reduced risk of death in patients with a history of cardiovascular disease, according to results from the observational Moli-sani study presented at ESC Congress 2016 today.1

read more

A new class of drugs called HIF-2 inhibitors is more effective and better tolerated than the standard of care drug sunitinib in treating kidney cancer, researchers with the Kidney Cancer Program at Harold C. Simmons Comprehensive Cancer Center have found.

read more

Using electric fans to relieve high levels of heat and humidity may, surprisingly, have the opposite effect for seniors, a study by UT Southwestern Medical Center heart specialists suggests.

read more

Farber Cancer Institute investigators report they have discovered a type of immune antibody that can rapidly evolve to neutralize a wide array of influenza virus strains - including those the body hasn't yet encountered.

read more

Natural predators of agricultural pests are influenced by the type and range of habitats within a farming landscape. A new study has developed an approach which predicts the risk of pest infestation and natural predation according to landscape features, to help land managers structure landscapes that encourage natural pest control.

A recent study has revealed that grassland plots planted with a mixture of several agricultural plant species produced a greater yield than plots planted with a single species. The findings provide valuable evidence for scientists, farmers and policymakers who strive to increase the productivity of grassland, while reducing input of nitrogen fertilisers.

The discomfort associated with hot, dry summers in some urban areas can be reduced by planting the most appropriate trees in open city spaces, according to a recent study. The researchers identified the Indian laurel fig as the most effective tree for this purpose in the Greek city of Chania.

A target level of 20 micrograms of phosphorus per litre of lake water could help keep many lakes safe for recreation by restricting the growth of harmful algal blooms, European research suggests. The scientists analysed the relationship between phosphorus levels in medium- and high-alkalinity lakes, the growth of cyanobacteria blooms and the concentrations of cyanobacteria that trigger World Health Organization (WHO) warnings.

Dry soils and a lack of cloud cover help explain a major heatwave in France, concludes new research. The study indicates that the two drivers were separate, unlinked events that came together at the same time to worsen the 2006 heatwave. Its findings could allow heatwaves to be predicted more accurately to protect public health.